Tang C, Zhou K, Zhu Y, Zhang W, Xie Y, Wang Z, et al
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
Patients with elevated nighttime inflammatory markers may benefit from evening dosing to support circadian repair, while those with daytime oxidative stress show better response to morning protocols that preload antioxidant defenses before peak exposure hours
Ipamorelin is an increasingly popular choice for those looking to improve their health and performance
